John M. Gay was named Chief Financial Officer of Pelthos Therapeutics Inc., effective April 10, 2026. As of November 6, 2026, Pelthos Therapeutics Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 10, 2026, naming 2 appointments (Form 8-K, April 10, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Pelthos Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Pelthos Therapeutics Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-10. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Pelthos Therapeutics Inc. files it.
Also on the record for Pelthos Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 3, 2026 | Stake report, Schedule 13D/A, by Ligand Pharmaceuticals Incorporated | 49.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Ikarian Capital, LLC | 7.7% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G/A, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Ikarian Capital, LLC | 8.4% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
| November 19, 2025 | Form D, private offering | $18M sold | Form D page | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Murchinson Ltd. | 9.1% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Ikarian Capital, LLC | 6.1% of the class | 5%+ stakes | Source |
| November 10, 2025 | Stake report, Schedule 13D/A, by Ligand Pharmaceuticals Incorporated | 49.9% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G/A, by AME Equities LLC | — | 5%+ stakes | Source |
| July 10, 2025 | Form D, private offering | $50.10M sold | Form D page | Source |
| July 8, 2025 | Stake report, Schedule 13G, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Pelthos Therapeutics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Pelthos Therapeutics Inc. and the records around it.
Pelthos Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Form D filing Nov 2025
- Form D filing Jul 2025
- Who owns it
Companies that share a holder
- Ligand Pharmaceuticals Incorporated also filed stake reports on 1 other company: XOMA ROYALTY CORPORATION (May 2026)
- Murchinson Ltd. also filed stake reports on 2 other companies: Nano Dimension Ltd. (Oct 2026), Valion Bio, Inc. (Jul 2026)
- 3i, LP also filed stake reports on 11 other companies: Tivic Health Systems, Inc. (Sep 2026), Netcapital Inc. (May 2026), zSpace, Inc. (Apr 2026)
Watch Pelthos Therapeutics Inc.
Get an email when Pelthos Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Pelthos Therapeutics Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Pelthos Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pelthos Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-10 | In | Chief Financial Officer | 2026-04-10 | 8-K, 2026-04-10 | |
| 2026-04-10 | In | 2026-04-10 | 8-K, 2026-04-10 |
Who leads Pelthos Therapeutics Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: John M. Gay, appointed, effective 2026-04-10 (filed 2026-04-10).
New leaders reset buying decisions — get the Full Report on Pelthos Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Pelthos Therapeutics Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Pelthos Therapeutics Inc.Every change, in the filing's words
Appointed: John M. Gay, Chief Financial Officer, effective 2026-04-10
On April 6, 2026, the Board of Directors (the "Board") of Pelthos Therapeutics Inc. (the "Company") appointed John M. Gay, age 49, to serve as Chief Financial Officer of the Company, effective April 10, 2026.
Appointed: John M. Gay, effective 2026-04-10
Also on April 10, 2026, the Board appointed Mr. Gay to serve as the Company's treasurer and secretary, effective April 10, 2026.
- Prior to joining the Company in July 2025 as Senior Vice President, Finance & Accounting, Mr. Gay served as Chief Financial Officer of LNHC, Inc. (then, a wholly owned subsidiary of Ligand Pharmaceuticals, Inc.), after the acquisition of ZELSUVMI in September 2023.
- Prior to joining LNHC, Mr. Gay served as Chief Financial Officer and Secretary for Novan, Inc. from September 2020 to September 2023, Vice President of Finance and Corporate Controller from January 2019 to September 2020, and Senior Director of Finance and Corporate Controller from May 2018 to January 2019.
- Previously, Mr. Gay served as Director of Finance for Valassis Digital from January 2018 to April 2018 and Director of SEC Reporting for MaxPoint Interactive, Inc., which was acquired by Valassis Digital, from May 2014 to April 2018.
- From June 2010 to May 2014, Mr. Gay held the Corporate Controller position at Furiex Pharmaceuticals, Inc. Prior to June 2010, Mr. Gay served in roles of increasing responsibility at two registered public accounting firms - Deloitte from July 2002 to May 2010 and Arthur Andersen from September 2000 to June 2002.
- Mr. Gay is a North Carolina certified public accountant and holds Bachelor's degrees in Economics and History and a Master's in Accounting degree from the University of North Carolina at Chapel Hill.
Tools for this story
Each opens in a new tab, filled in for Pelthos Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.